Trial reportCardiovascular diabetology2022
Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease.
Trial report in Cardiovascular diabetology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04580173 (Correlation of Clinical Types and Complexity of Coronary Artery Disease With Patients' Metabolic Profile), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Correlation of Clinical Types and Complexity of Coronary Artery Disease With Patients' Metabolic Profile
Who cites it
38 citing papers in PubMed, 55 citations in OpenAlex.
- Development and external validation of an admission-based model for 180-day mortality in diabetic acute myocardial infarction.Frontiers in endocrinology · 2026Article
- Effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with type 2 diabetes Mellitus and coronary heart disease.Frontiers in cardiovascular medicine · 2026Article
- Plasma metabolomics disentangles T2DM- and CAD-specific dysmetabolism and identifies potential biomarkers for CAD risk escalation in diabetic patients.Cardiovascular diabetology · 2025Article
- Role of annexin A7 in the occurrence and progression of coronary atherosclerosis: a narrative review.Cardiovascular diagnosis and therapy · 2025Review
- Predicting the prognosis of diabetic patients undergoing percutaneous coronary intervention: the value of the Naples prognostic score in a real-world clinical study.BMC cardiovascular disorders · 2025Observational
- The relationship between ABO blood types and clopidogrel-related low on-treatment platelet reactivity in patients with coronary artery diseases and type 2 diabetes mellitus: a secondary analysis of a prospective cohort study.Diabetology & metabolic syndrome · 2025Article
- Advancements in Biomarkers for Early Detection and Risk Stratification of Cardiovascular Diseases-A Literature Review.Health science reports · 2025Article
- Coronary imaging characteristics and risk factors in patients with type 2 diabetes mellitus with coronary heart disease complication.World journal of diabetes · 2025Article
- Pregnancy as a Susceptible Period to Ambient Air Pollution Exposure on the Maternal Postpartum Metabolome.Environmental science & technology · 2025Article
- Usefulness of the Córdoba Equation for Estimating Body Fat When Determining the Level of Risk of Developing Diabetes Type 2 or Prediabetes.Medicina (Kaunas, Lithuania) · 2025Article
- Ceramide in Coronary Artery Disease: Troublesome or Helpful Future Tools in the Assessment of Risk Prediction and Therapy Effectiveness?Metabolites · 2025Review
- Interferon-induced transmembrane proteins as biomarkers for assessing the diagnosis and severity of coronary artery disease and acute myocardial infarction.Frontiers in medicine · 2025Article
- Machine Learning based Model Reveals the Metabolites Involved in Coronary Artery Disease.Biomedical engineering and computational biology · 2025Article
- Platelet-to-Hemoglobin Ratio in Predicting Major Adverse Cardiovascular Events After Coronary Artery Bypass Grafting.Vascular health and risk management · 2025Article
- Metabolic perturbations in cardiomyopathies: implications for early diagnosis and targeted interventions.Frontiers in cardiovascular medicine · 2025Review
- Development and External Validation of a Machine Learning-Based Model for Predicting Heart Failure Risk in Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- A global perspective on the status of clinical metabolomics in laboratory medicine - a survey by the IFCC metabolomics working group.Clinical chemistry and laboratory medicine · 2024Article
- Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems biology.npj metabolic health and disease · 2024Review
- Biomarker Profiling with Targeted Metabolomic Analysis of Plasma and Urine Samples in Patients with Type 2 Diabetes Mellitus and Early Diabetic Kidney Disease.Journal of clinical medicine · 2024Article
- Unveiling the future: precision pharmacovigilance in the era of personalized medicine.International journal of clinical pharmacy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) and coronary artery disease (CAD) constitute inter-related clinical entities. Biomarker profiling emerges as a promising tool for the early diagnosis and risk stratification of either DM or CAD. However, studies assessing the predictive capacity of novel metabolomics biomarkers in coexistent CAD and DM are scarce.
methodsThis post-hoc analysis of the CorLipid trial (NCT04580173) included 316 patients with CAD and comorbid DM who underwent emergency or elective coronary angiography due to acute or chronic coronary syndrome. Cox regression analyses were performed to identify metabolomic predictors of the primary outcome, which was defined as the composite of major adverse cardiovascular or cerebrovascular events (MACCE: cardiovascular death, myocardial infarction, stroke, major bleeding), repeat unplanned revascularizations and cardiovascular hospitalizations. Linear regression analyses were also performed to detect significant predictors of CAD complexity, as assessed by the SYNTAX score.
resultsAfter a median 2-year follow up period (IQR = 0.7 years), the primary outcome occurred in 69 (21.8%) of patients. Acylcarnitine ratio C4/C18:2, apolipoprotein (apo) B, history of heart failure (HF), age > 65 years and presence of acute coronary syndrome were independent predictors of the primary outcome in diabetic patients with CAD (aHR = 1.89 [1.09, 3.29]; 1.02 [1.01, 1.04]; 1.28 [1.01, 1.41]; 1.04 [1.01, 1.05]; and 1.12 [1.05-1.21], respectively). Higher levels of ceramide ratio C24:1/C24:0, acylcarnitine ratio C4/C18:2, age > 65 and peripheral artery disease were independent predictors of higher CAD complexity (adjusted β = 7.36 [5.74, 20.47]; 3.02 [0.09 to 6.06]; 3.02 [0.09, 6.06], respectively), while higher levels of apoA1 were independent predictors of lower complexity (adjusted β= - 0.65 [- 1.31, - 0.02]).
conclusionsIn patients with comorbid DM and CAD, novel metabolomic biomarkers and metabolomics-based prediction models could be recruited to predict clinical outcomes and assess the complexity of CAD, thereby enabling the integration of personalized medicine into routine clinical practice. These associations should be interpreted taking into account the observational nature of this study, and thus, larger trials are needed to confirm its results and validate them in different and larger diabetic populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.